Claudia Ordonez, Chief Medical Officer at Keros Therapeutics, Inc. (KROS), sold 1,000 shares at $61.23 ($60K) on 2021-04-12, disclosed to the SEC on 2021-04-14.
Scheduled sale ($60k) by Chief Medical Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $59.09 | 400 | $24K | 39.4% |
| 2 | $60.01 | 367 | $22K | 36.8% |
| 3 | $61.23 | 233 | $14K | 23.8% |
| Total | $59.93 avg | 1,000 | $60K | 100% |
| Filing → |
| KROS | SELL | 2021-03-15 | $65K | — | Filing → |
| KROS | SELL | 2021-02-16 | $65K | — | Filing → |